New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin

Journal of Medicinal Chemistry

Volumn 51, Issue 7, 2008, Pages 2009-2017

  Lázaro, Elisabet ^a   Lowe, Philip J ^b   Briand, Xavier ^b   Faller, Bernard ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; DESIPRAMINE; DIAZEPAM; DICLOFENAC; DIFLUNISAL; HUMAN SERUM ALBUMIN; OXAZEPAM; PROPRANOLOL; QUININE; TOLBUTAMIDE; VERAPAMIL; WARFARIN;

ADSORPTION; ARTICLE; ARTIFICIAL MEMBRANE; BINDING AFFINITY; OSMOTIC PRESSURE; PROTEIN BINDING; WATER PERMEABILITY;

HUMANS; KINETICS; MEMBRANES, ARTIFICIAL; PERMEABILITY; PROTEIN BINDING; SERUM ALBUMIN;

EID: 41849121510     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7012826     Document Type: Article

References (46)

1. Kurz, H.; Trunk, H.; Weitz, B. Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneim.-Forsch. 1977, 27, 1373-1380.
2. Bowers, W. F.; Fulton, S.; Thompson, J. Ultrafiltration vs equilibrium dialysis for determination of free fraction. Clin. Pharmacokinet. 1984, 9, 49-60.
3. Sebille, B.; Zini, R.; Madjar, C. V.; Thuaud, N.; Tillement, J. P. Separation procedures used to reveal and follow drug-protein binding. J. Chromatogr., A 1990, 531, 51-77.
4. Fung, E. N.; Chen, Y.; Lau, Y. Y. Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J. Chromatogr., B 2003, 795, 187-194.
5. Wan, H.; Rehngren, M. High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry. J. Chromatogr., A 2006, 1102, 125-134.
6. Banker, M: J.; Clark, T. H.; Williams, J. A. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J. Pharm. Sci. 2003, 92 (5), 967-974.
7. Gabay, S.; Huang, P. C. The binding behavior of phenothiazines and structurally related compounds to albumin from several species. Adv. Biochem. Psychopharmacol. 1974, 9, 175-189.
8. Brodersen, R.; Sjodin, T.; Sjoholm, I. Independent binding of ligands to human serum albumin. J. Biol. Chem. 1977, 252, 5067-5072.
9. Valko, K.; Nunhuck, S.; Bevan, C.; Abraham, M. H.; Reynolds, D. P. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J. Pharm. Sci. 2003, 92, 2236-2248.
10. Hollosy, F.; Valko, K.; Hersey, A.; Nunhuck, S.; Keri, G.; Bevan, C. Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning. J. Med. Chem. 2006, 49, 6958-6971.
11. Hartmann, T.; Schmitt, J.; Rohring, C.; Nimptsch, D.; Noller, J.; Mohr, C. ADME related profiling in 96 and 384 well plate format - A novel and robust HT-assay for the determination of lipophilicity and serum albumin binding. Curr. Drug Delivery 2006, 3, 181-192.
12. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 1998, 41 (7), 1007-1010.
13. Wohnsland, F.; Faller, B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J. Med. Chem. 2001, 44, 923-930.
14. Sugano, K.; Nabuchi, Y.; Machida, M.; Aso, Y. Prediction of human intestinal permeability using artificial membrane permeability. Int. J. Pharm. 2003, 257 (1-2), 245-251.
15. Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. Parallel artificial membrane permeability assay (PAMPA)-critical factors for better predictions of absorption. J. Pharm. Sci. 2007 96, (11), 2893-2909.
16. Berkeley Madonna, http://www.berkeleymadonna.com/, http://www. berkeleymadonna.com/BM%20User's%20Guide%208.0.pdf,accessed 31-Aug-2007.
17. Zaton, A. M.; Ferrer, J. M.; Ruiz de Gordoa, J. C.; Marquinez, M. A. Binding of coumarins to site I of human serum albumin. Effect of the fatty acids. Chem.-Biol. Interact. 1995, 97, 169-174.
18. Kragh-Hansen, U. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. Mol. Pharmacol. 1988, 34, 160-171.
19. Kragh-Hansen, U. Relations between high-affinity binding sites of markers for binding regions on human serum albumin. Biochem. J. 1985, 225, 629-638.
20. Vestberg, K.; Galliano, M.; Minchiotti, L.; Kragh-Hansen, U. High-affinity binding of warfarin, salicylate and diazepam to natural mutants of human serum albumin modified in the C-terminal end. Biochem. Pharmacol. 1992, 44, 1515-1521.
21. Sengupta, A.; Hage, D. S. Characterization of minor site probes for human serum albumin by high-performance affinity chromatography. Anal. Chem. 1999, 71, 3821-3827.
22. Brown, K. F.; Crooks, M. J. Displacement of tolbutamide, glibencalmide, and chlorpropamide from serum albumin by anionic drugs. Biochem. Pharmacol. 1976, 25, 1175-1178.
23. Chattopadhyay, A.; Tian, T.; Kortum, L.; Hage, D. S. Development of tryptophan-modified human serum albumin columns for site-specific studies of drug-protein interactions by high-performance affinity chromatography. J. Chromatogr., B: Biomed. Sci. Appl. 1998, 715, 183-190.
24. Paubel, J. P.; Niviere, P. La liaison des molécules organiques thérapeutiques avec les protéines: Cas de la quinine. Eur. J. Med. Chem. 1974, 9, 508-512.
25. Sharples, D. Competition for plasma protein binding sites between phenothiazine tranquilizers and iminodibenzyl antidepressants. J. Pharm. Pharmacol. 1975, 27, 379-381.
26. Szymura-Oleksiak, J.; Wyska, E.; Wasieczko, A. Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology (Berlin) 2001, 154, 38-42.
27. Honore, B.; Brodersen, R. Albumin binding of anti-inflammatory drugs. Utility of a site-oriented versus a stoichiometric analysis. Mol. Pharmacol. 1984, 25, 137-150.
28. Larsen, C. G.; Larsen, F. G.; Jakobsen, P.; Brodersen, R. Multiple cobinding of two ligands to serum albumin: a stoichiometric description of binding equilibria. Arch. Biochem. Biophys. 1985, 239, 74-86.
29. Huang, P. C.; Gabay, S. Examination of phenothiazine-albumin interaction by ultraviolet difference spectrophotometry. Biochem. Pharmacol. 1974, 23, 957-972.
30. Nambu, N.; Nagai, T. Binding of phenothiazines to bovine serum albumin and related phenomena. Chem. Pharm. Bull. (Tokyo) 1972, 20, 2463-2470.
31. Romer, J.; Bickel, M. H. A method to estimate binding constants at variable protein concentrations. J. Pharm. Pharmacol. 1979, 31, 7-11.
32. Bagatolli, L. A.; Kivatinitz, S. C.; Fidelio, G. D. Interaction of small ligands with human serum albumin IIIA subdomain. How to determine the affinity constant using an easy steady state fluorescent method. J. Pharm. Sci. 1996, 85, 1131-1132.
33. Viani, A.; Cappiello, M.; Pacifici, G. M. Binding of diazepam, salicylic acid, and digitoxin to albumin isolated from fetal and adult serum. Dev. Pharmacol. Ther. 1991, 17, 100-108.
34. Wilting, J.; Hart, B. J.; De Gier, J. J. The role of albumin conformation in the binding of diazepam to human serum albumin. Biochim. Biophys. Acta 1980, 626, 291-298.
35. Lucas, D.; Menez, J. F.; Daniel, J. Y.; Bardou, L. G.; Floch, H. H. Acetaldehyde adducts with serum proteins: Effect on diazepam and Phenytoin binding. Pharmacology 1986, 32, 134-140.
36. Kober, A.; Ekman, B.; Sjoholm, I. Direct and indirect determination of binding constants of drug-protein complexes with microparticles. J. Pharm. Sci. 1978, 67, 107-109.
37. Muller, W.; Wollert, U. Characterization of the binding of benzodiazepines to human serum albumin. Naunyn-Schmiedeberg's Arch. Pharmacol. 1973, 280, 229-237.
38. Chamouard, J. M.; Barre, J.; Urien, S.; Houin, G.; Tillement, J. P. Diclofenac binding to albumin and lipoproteins in human serum. Biochem. Pharmacol. 1985, 34, 1695-1700.
39. Epps, D. E.; Raub, T. J.; Kezdy, F. J. A general, wide-rage spectrofluorometric method for measuring the site-specific affinities of drugs toward human serum albumin. Anal. Biochem. 1995, 227, 342-350.
40. Zini, R. Les modes de fixation des médicaments sur les proteines plasmatiques humaines et leurs conséquences pharmacologiques. UER de Sciences de l'Université Paris XII, France, Dissertation, 1984.
41. Tanaka, M.; Asahi, Y.; Masuda, S.; Minagawa, K. Binding position of tolbutamide to human serum albumin. Chem. Pharm. Bull. (Tokyo) 1998, 46, 817-821.
42. Judis, J. Binding of sulfonylureas to serum proteins. J. Pharm. Sci. 1972, 61, 89-93.
43. Zini, R.; d'Athis, P.; Hoareau, A.; Tillement, J. P. Binding of four sulphonamides to human albumin. Eur. J. Clin. Pharmacol. 1976, 10, 139-145.
44. Jakoby, M. G. 4th.; Covey, D. F.; Cistola, D. P. Localization of tolbutamide binding sites on human serum albumin using titration calorimetry and heteronuclear 2-D NMR. Biochemistry 1995, 34, 8780-8787.
45. Koizumi, K.; Ikeda, C.; Ito, M.; Suzuki, J.; Kinoshita, T.; Yasukawa, K.; Hanai, T. Influence of glycosylation on the drug binding of human serum albumin. Biomed. Chromatogr. 1998, 12, 203-210.
46. Ding, Y.; Zhu, X.; Lin, B. Study of interaction between drug enantiomers and serum albumin by capillary electrophoresis. Electrophoresis 1999, 20, 1890-1894.